MRES: M2Bio Sciences Appoints Adrian J. Maizey,
Accomplished CEO and Financial Expert, to Advisory
Board
CAPE TOWN,
SOUTH AFRICA -- July 19, 2023 -- InvestorsHub NewsWire
-- Institute of Biomedical Research Corp. (OTC
PINK: MRES) ("Institute of Biomedical Research" or the
"Company"), a nutraceutical biotechnology company focused on
alternative plant-based cannabinoids, medical psilocybin and mental
health therapeutic research powered by artificial intelligence, and
evidence-based sustainable products and solutions, is pleased to
share the following update:
M2Bio
Sciences, a trailblazing biotechnology company committed to
pioneering groundbreaking research, is proud to announce the
appointment of
Adrian Maizey to its esteemed Advisory
Board. A
distinguished leader and financial and data analytics expert,
Adrian Maizey brings a wealth of experience and expertise from his
prior roles in top-tier firms with a focus spanning New York Stock
Exchange and Johannesburg Stock Exchange companies, the US private
equity and hedge fund industries, and South African private
consumer retail companies.
Adrian
Maizey is the Chief Executive Officer of Rand Capital Coffee, the
exclusive licensee for Starbucks in Southern Africa. Founded in
2019, Rand Capital Coffee owns and operates 65 Starbucks cafes
across Southern Africa, a testament to Adrian's remarkable
leadership in the region's food and beverage industry. Rand Capital
Coffee is a subsidiary of Rand Capital, an investment advisory firm
Adrian founded in 2012.
Prior to
his role at Rand Capital, Adrian held several key positions in
prestigious financial and investment firms, showcasing his
versatile capabilities. Notably, Adrian served as the Chief
Financial and Chief Compliance Officer of ESL Investments, Inc., a
group of long-term concentrated value investment funds founded by
legendary investor Edward S. Lampert. During his tenure, ESL
managed $22 billion and held core investments in companies such as
Sears Holdings, AutoNation, and AutoZone. Adrian oversaw the
company's operations, including legal, tax, accounting, treasury,
finance, investor relations, research, marketing, and compliance
departments.
Adrian's
vast experience also includes serving as the Chief Operating
Officer and Chief Compliance Officer of Leonard Green &
Partners, L.P., a leading Los Angeles-based private equity firm
with $70 billion under management. Adrian managed the firm's
operations, including its legal, regulatory, and compliance
functions, and oversaw accounting, tax, investor relations, and
marketing activities.
Additionally,
Adrian was a partner at RedBird Capital Partners, a New York City
private equity firm. Redbird manages $8.6 billion of capital
principally across its core industry verticals in Sports, TMT,
Consumer and Financial Service. Adrian held the titles of Chief
Financial Officer, Chief Operating Officer, and Compliance Officer
and he was responsible for establishing the firm's infrastructure
and all financial reporting, controllership, treasury, tax,
budgeting, fund management and administrative services, as well as
the firm's compliance and regulatory obligations. Adrian was a
member of each investment deal team to help lead financial and
accounting due diligence as well as tax structuring
oversight.
Moreover,
Adrian's career highlights encompass leadership roles at Deloitte
& Touche LLP, where he spent a decade as a management
consultant, working extensively with clients in the investment
management and energy industries. His responsibilities included
leading forensic investigations and managing purchase price dispute
litigation engagements for Fortune 500 companies with an emphasis
on data analytics. Adrian is credited with developing and
distributing Deloitte's proprietary exploratory data analysis
software for detecting financial statement fraud.
Adrian's
academic credentials are equally commendable. He earned an MBA from
Harvard Business School in 2003 and holds a Bachelor of Business
Administration degree with distinction in Accounting from the
University of Nebraska. His early education includes studies at the
University of Pretoria and matriculation from Pretoria Boy's High
School, both institutions Elon Musk attended during the same
era.
In addition
to his professional accomplishments, Adrian's exceptional
dedication to physical challenges is evident in his completion of
22 Ironman triathlons, four ultra-marathons (including three
Comrades marathons), and 25 standard marathons. In 2022, Adrian
completed the Cape Epic, a multi-stage mountain bike race spanning
over 430 miles with 55,400 feet of climbing. He is also a former US
collegiate Division I tennis conference champion.
Expressing
his excitement about joining M2Bio Sciences' Advisory Board, Adrian
Maizey said,
"Joining M2Bio Sciences is invigorating. I am thrilled to be
surrounded by a team of curious and brilliant minds, all fueled by
a shared passion for innovation and excellence. The opportunity to
contribute to Jeff Robinson's vision and ambition in growing this
quality company is a privilege. I eagerly anticipate the remarkable
achievements and discoveries that await us on this exciting
journey."
Jeff Robinson, CEO of M2Bio Sciences, warmly
welcomed Adrian Maizey to the Advisory Board, stating,
"We are thrilled to have Adrian Maizey on board with us. His
extensive experience in the financial and investment sectors,
coupled with his outstanding leadership at Starbucks SA, make him
an invaluable addition to our Advisory Board. Adrian's insights and
strategic acumen will undoubtedly play a pivotal role in propelling
M2Bio Sciences to new heights. We look forward to working closely
with him as we strive to revolutionize the biotechnology
landscape."
Adrian
Maizey's appointment to the Advisory Board further reinforces M2Bio
Sciences' commitment to fostering innovation and advancing
transformative solutions in the biotechnology arena.
About Institute of
Biomedical Research Corp./ DBA M2Bio Sciences
Institute of Biomedical Research
Corp, is a nutraceutical biotechnology company focused on
alternative plant-based cannabinoids, medical psilocybin and mental
health therapeutic research powered by artificial intelligence, and
evidence-based sustainable products and solutions, that develops
and commercializes a range of CBD and mushrooms-based products
under Dr. AnnaRxâ„¢, Medspressoâ„¢, Livianaâ„¢ brands as well as
artificial intelligence powered nutrition products and solutions
under the M2Biome brand. In addition, our research and clinical
trials with psilocybin are aimed at new therapies that will help
patients who suffer from alcohol addiction, mental illness, and
cardiovascular diseases. Our mission is to advance botanical-based
medicine to the forefront by deploying best-practice science and
medicine, clinical research, and emerging technologies such as
artificial intelligence. The Company is traded on the
Over-the-Counter Bulletin Board of NASDAQ under the trading symbol
"MRES".
Publicly traded Company (OTC
Pink: MRES)
www.m2bio.co
jeff@m2bio.co
+27 72 333 2148
Find M2Bioâ„¢ on
social media
Facebook: M2Bio
Instagram: M2bio.Sciences
LinkedIn: M2Bio
Twitter: @M2bio
Forward-Looking
Statements
Safe Harbour Statement - In addition
to historical information, this press release may contain
statements that constitute forward-looking statements within the
meaning of the Securities Act of 1933 and the Securities Exchange
Act of 1934, as amended by the Private Securities Litigation Reform
Act of 1995. Forward-looking statements contained in this press
release include the intent, belief, or expectations of the Company
and members of its management team with respect to the Company's
future business operations and the assumptions upon which such
statements are based. Prospective investors are cautioned that any
such forward-looking statements are not guarantees of future
performance, involve risks and uncertainties and that actual
results may differ materially from those contemplated by such
forward-looking statements. Factors that could cause these
differences to include, but are not limited to, failure to complete
anticipated sales under negotiations, lack of revenue growth,
client discontinuances, failure to realize improvements in
performance, efficiency, and profitability, and adverse
developments with respect to litigation or increased litigation
costs, the operation or performance of the Company's business units
or the market price of its common stock. Additional factors that
could cause actual results to differ materially from those
contemplated within this press release can also be found on the
Company's website. The Company disclaims any responsibility to
update any forward-looking statements. mres
Institute of Biomedical ... (PK) (USOTC:MRES)
Historical Stock Chart
From Dec 2024 to Jan 2025
Institute of Biomedical ... (PK) (USOTC:MRES)
Historical Stock Chart
From Jan 2024 to Jan 2025